Abstracts

Delayed HIV Detection in Infants Exposed to ARV Prophylaxis During Breastfeeding

Background: We reported on the effectiveness of 28 weeks of infant nevirapine or maternal antiretrovirals in preventing HIV transmission during breastfeeding from a randomized trial of 2369 mother-infant pairs: the Breastfeeding, Antiretrovirals and Nutrition (BAN) study. After counseling on breastfeeding cessation and stopping the antiretroviral intervention, 28 infections were detected from 29 to 48 weeks:…

Evaluation of the Alere q for Point-of-Care Early Infant HIV Diagnosis in South Africa

Background: New point-of-care (POC) HIV molecular diagnostic tools could fundamentally alter early infant HIV diagnosis (EID) and management in resource-limited settings by reducing the time to initiation of antiretroviral therapy and promoting retention in care. However few technologies have been independently evaluated and data on new technologies are urgently required. Methods: We investigated the analytic…

Early ART and Sustained Virological Suppression Limits HIV Proviral DNA Reservoir: CHER Evidence

Background: Improved understanding of HIV-1 proviral DNA latent reservoir formation and impact of ART-strategies on reservoir size can inform treatment strategies in paediatric HIV. Methods: HIV-1 proviral DNA was measured from a substudy of 118 children from the Children with HIV Early Antiretroviral Therapy (CHER) trial where HIV-infected infants <12 weeks with CD4% ≥25% were…

Long-Term Outcomes of HIV-Infected Children Initiating NVP vs LPV/r-Based Treatment

Background: IMPAACT P1060 demonstrated short-term superiority of lopinavir/ritonavir (LPV/r)-based ART over nevirapine (NVP) for the primary endpoint (stopping randomized treatment, virologic failure [VF] or death by 24 weeks) in HIV-infected children regardless of NVP exposure at birth. In contrast, those on NVP had marginally superior improvements in CD4% and growth (weight and height z-scores). Longer-term…

Structural Cardiovascular Changes Are Reversible in HIV-Infected Children in Zambia and Uganda.

Background: Carotid intimal medial thickness (IMT) and pulse wave velocity (PWV), as measures of cardiovascular structure/function, are impaired in HIV-infected children in high-income countries. Few longitudinal data are available: none come from Africa where 90% HIV-infected children live. Methods: ART-naïve and ART-experienced (on d4T+3TC+NNRTI for >2years, virologically suppressed at enrolment) HIV-infected children had IMT and…

ART With Weekends Off Is Noninferior to Continuous ART in Young People on EFV+2NRTI

Background: For HIV-1 infected young people (YP) facing lifelong ART, short cycle therapy (SCT) with long-acting agents offers the potential for drug-free weekends, less toxicity and better adherence, as well as cost savings. Methods: BREATHER is a randomised, non-inferiority trial in Europe, Thailand, Uganda, Argentina & US. YP (>8, ≤24 yrs) on efavirenz (EFV)+2NRTIs and…

HIV-1 Accessory Protein Function: Evaluating VPU-Dependent Host Factor Degradation

Background: Cellular proteins called “restriction factors” are important in counteracting HIV-1 infection through cell intrinsic immune mechanisms. BST2 (Tetherin) is a cellular factor that prevents virion release by trapping HIV-1 on the plasma membrane. The HIV-1 accessory protein VPU is known to down-regulate BST2, thereby aiding in virion release. We hypothesize that VPU may target…

The HIV-1 Protease Can Interact With RNA to Dramatically Enhance Its Activity

Background: In the maturation step of the HIV-1 lifecycle, the virus-encoded protease (PR) must process the structural polyprotein Gag to generate infectious virus particles. Previous reports found that cleavage of the p15NC maturation intermediate accelerates when RNA is present. Our studies have shown RNA-enhancement is substrate-independent. We hypothesize that enhancement results from an interaction between…